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Biol. Chem. 279, 24108–24115.protein (Baneres and Parello, 2003). Stable crosslinking
Lesort, M., Tucholski, J., Miller, M.L., and Johnson, G.V. (2000). Prog.of AT1 dimers may provide a kinetically favorable inter-
Neurobiol. 61, 439–463.face for interaction with G proteins as compared with a
Lorand, L., and Graham, R.M. (2003). Nat. Rev. Mol. Cell Biol. 4,dissociable receptor complex. However, recent findings
140–156.suggest the existence of constitutively active AT1 recep-
tors, which appear to form stable dimers independent
of covalent crosslinking (Hansen et al., 2004). It remains
to be determined how the covalent AT1 dimers differ from
the preformed AT1 dimers that are not covalently linked. Chronic Myeloid Leukemia:
It will also be of interest to determine whether analo-
Proving Ground for Cancergous mechanisms apply to other GPCR homo- or het-
erodimeric pairings. A factor XIIIA-dependent crosslink- Stem Cells
ing mechanism may be unique for AT1 dimers, as AT1/
B2 receptor heterodimers are not sensitive to inhibition
of factor XIIIA. However, genome sequencing efforts
have revealed the existence of 700–800 mammalian A central question in cancer biology is whether malig-
nancy arises in self-renewing tissue stem cells thatGPCRs, about 250 of which are identified as receptors
for known ligands, with the rest still classified as orphan suffer oncogene activation or in differentiated cells
that acquire properties of unremitting self-renewal?receptors (oGPCRs). The identification of transglutami-
nase-dependent crosslinking as a regulatory mecha- In two papers, Weissman and colleagues document
both mechanisms: chronic leukemia arising by muta-nism for other GPCRs could be of potential importance
in drug discovery efforts. The present studies also raise tion affecting the hematopoietic stem cell (HSC) and
acute leukemia evolving from committed granulocyte-the possibility that, in disorders, such as Huntington’s
disease and Alzheimer’s disease, with enhanced trans- macrophage progenitors that have acquired the self-
renewal machinery of HSCs.glutaminase expression and activity (Lesort et al., 2000),
covalent receptor dimer stabilization of specific GPCRs
apart from AT1 could be of pathological relevance. Po- Human chronic myeloid leukemia (CML) is a myeloprolif-
tential roles of other members of the transglutaminase erative disorder (MPD) caused by the Philadelphia chro-
family are unclear. For example, in contrast to factor mosome translocation, a t(9;22) that generates the BCR/
XIIIA, transglutaminase 2 (tissue transglutaminase) was ABL fusion oncoprotein. Several features suggest that
not effective in stabilizing angiotensin II-induced AT1 CML has its origins in the HSC. The Philadelphia chro-
dimers (AbdAlla et al., 2004; Lorand and Graham, 2003). mosome can be detected in both myeloid and lymphoid
The dynamic interplay between constitutive GPCR cells, and evolution of the disease into an acute leukemia
clustering, ligand-induced receptor rearrangements, can affect either the myeloid or lymphoid lineages. Rein-
and specific biological or pathological outcomes will be forcing its stem cell origins, traditional cytotoxic chemo-
a significant avenue of future investigation (Franco et therapy fails to induce a cytogenetic remission in CML.
al., 2003). The discovery that factor XIIIA-dependent In murine models, when retroviruses specifying BCR/
crosslinking of AT1 receptors potentiates angiotensin II ABL infect the hematopoietic stem cell (as evidenced
signaling raises the possibility that inhibition of covalent by common retroviral integration sites in myeloid and
dimer formation might provide the basis for novel thera- lymphoid lineages), the resulting disease closely resem-
peutic interventions. bles human CML (Daley et al., 1990; Li et al., 1999). In
contrast, when retroviruses infect committed progeni-
tors, acute leukemias arise with a single proviral integra-Sumito Ogawa and Christopher K. Glass
tion site, implying the selection of a leukemic subclone
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carrying additional genetic changes. Leukemia thus pro-
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In this issue of Cell, Passegue et al. examine the leuke-
mic target cells of mice engineered with genetic loss of
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thality, transgenic expression of junB under control ofAbdAlla, S., Lother, H., el Massiery, A., and Quitterer, U. (2001). Nat.
a ubiquitous promoter (junB//Ubi-junB) rescues viabil-Med. 7, 1003–1009.
ity. These mice inevitably develop a CML-like MPD withAbdAlla, S., Lother, H., Langer, A., el Faramawy, Y., and Quitterer,
a predominance of granulocytes and a natural tendencyU. (2004). Cell 119, this issue, 343–354.
to evolve into leukemic blast crisis (Passegue et al.,Baneres, J.L., and Parello, J. (2003). J. Mol. Biol. 329, 815–829.
2001). Curiously, the proliferating myeloid cells in theDaugherty, A., and Cassis, L. (2004). Trends Cardiovasc. Med. 14,
junB//Ubi-junB mice have silenced junB function sto-117–120.
chastically, thereby implying that loss of junB functionFranco, R., Canals, M., Marcellino, D., Ferre, S., Agnati, L., Mallol,
drives increased self-renewal of HSCs. This conclusionJ., Casado, V., Ciruela, F., Fuxe, K., Lluis, C., and Canela, E.I. (2003).
Trends Biochem. Sci. 28, 238–243. is corroborated by direct quantification of cells with a
surface antigen phenotype of the most primitive HSCsGlass, C.K., and Witztum, J. (2001). Cell 104, 503–516.
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(Kit, Sca-1, lineage negative, Flk-2), which are in- malignancies exploit the same self-renewal pathways
creased in the mice. as stem cells. In a paper published recently in the New
To directly link junB deficiency to MPD, the authors England Journal of Medicine (Jamieson et al., 2004),
selectively deleted junB in primitive and more mature Weissman and colleagues show that the GMP popula-
hematopoietic populations. They generated mice with tion in patients with advanced stage CML have in-
the junB alleles flanked by loxP recombination sites and creased nuclear localization of -catenin, which this
crossed these mice with a strain that expresses the cre group had previously linked to self-renewal in normal
recombinase from the MRP8 promoter, such that junB HSCs (Reya et al., 2003). In particular, the enhanced
would be deleted selectively in granulocytes and a sub- nuclear localization of -catenin was most notable in
set of the granulocyte-macrophage progenitor popula- the GMPs of patients in myeloid blast crisis, implying
tion (GMP) (Passegue´ et al., 2004). Interestingly, these that the evolution of the disease entails acquisition of
mice showed increased granulopoiesis but never self-renewal properties by progenitor cell targets that
evolved overt leukemia, suggesting that loss of junB typically do not self-renew. These data suggest that the
function in a non-self-renewing cell population like the leukemic stem cell for the blast crisis stage of CML (at
GMP is insufficient to induce MPD. In other experiments, least the myeloid form) is the GMP, by virtue of having
the junB floxed mice were crossed with strains speci- acquired the self-renewal phenotype of the HSC. Thus,
fying cre in a wider array of tissues, including an induc- blast crisis patients may harbor two classes of leukemic
ible MX-cre that affords efficient knockout of junB func- stem cells: (1) the GMP that harbors multiple oncogenic
tion in the most primitive HSCs. These mice developed activations (BCR/ABL, enhanced nuclear -catenin, and
the severe form of MPD. The MPD associated with junB a mutation that blocks cell differentiation); and (2) the
deficiency can be readily transplanted from one mouse original leukemic clone within the HSC compartment
to another, and the authors showed that the self-renewing itself. This model explains why blast crisis patients
population of cells that sustain this leukemia coincided treated with high-dose chemotherapy can sometimes
with long-term repopulating HSCs. Depletion of cells revert to the chronic phase and lose the complex cytoge-
expressing the stem cell marker c-Kit caused a loss netic abnormalities typical of the blast crisis clone. The
in transmissibility, and transplant of more committed difficulty of eradicating the leukemic clone from the HSC
progenitors again failed to transmit the MPD. These data pool underscores why induction chemotherapy typically
provide conclusive evidence that the junB-deficient fails to induce cytogenetic remission. This contrasts with
CML-like myeloproliferative disorder directly involves acute leukemias, in which chemotherapy can induce
the most primitive HSC in the bone marrow, and that complete remissions, because once the leukemic pro-
loss of junB function in more committed cells will not genitors are eradicated, normal hematopoiesis will re-
sustain leukemia. cover from a pristine pool of HSCs.
Given how closely the junB-deficient disease mimics If the critical oncogenic mutation must occur in the
human CML, one wonders whether BCR/ABL abrogates HSC in order to induce a CML-like MPD, then perhaps
junB function or whether junB silencing is obligatory in we need not worry when BCR/ABL transcripts are de-
the human disease. In this light, it is interesting to note tected in a significant percentage of normals (Biernaux
that junB is downregulated in a number of CML patients et al., 1996; Bose et al., 1998). If these aberrant tran-
(Biernaux et al., 1996; Bose et al., 1998). Retroviral mod- scripts arise due to chromosomal translocations in com-
els of MPD in mice provide an excellent system for mitted GMP progenitors, not the HSC, then they are
testing whether junB loss of function is an obligate fea- harmless alone and would require another unlucky
ture of transformation by BCR/ABL. One would predict event—like mutations leading to enhanced nuclear
that enforced coexpression of junB in a bicistronic
-catenin—to occur in precisely the same cell to pro-
vector might antagonize oncogenesis by BCR/ABL, duce a leukemic stem cell. The current studies highlight
whereas simultaneous gene knockdown might promote
the central importance that the cancer stem cell concept
more aggressive disease. If junB loss is central to CML
plays for understanding the mutational events that in-
pathogenesis, then finding a drug to target the signal
duce leukemia and remind us how a rare but molecularlytransduction pathway that downregulates junB expres-
defined disease like CML can establish important para-sion might provide an alternative treatment strategy for
digms for cancer biology.Gleevec-resistant CML patients. Why junB loss of func-
tion is so intimately tied to granulocytosis remains a
perplexing question, but if BCR/ABL indeed abrogates George Q. Daley
junB function, this might help explain the CML disease Division of Pediatric Hematology/Oncology
phenotype. Loss of function of another transcriptional Children’s Hospital, Boston
regulatory factor, the Interferon Consensus Sequence Department of Biological Chemistry and Molecular
Binding Protein (ICSBP) likewise produces a CML-like Pharmacology
MPD in mice, complete with the tendency to evolve into Harvard Medical School
acute leukemia (Holtschke et al., 1996). Whether junB Boston, Massachusetts 02115
and ICSBP are interdependent or represent two of sev-
eral genes whose loss of function deregulates myelo- Selected Reading
poiesis remain interesting questions for the future.
Another central question in cancer biology is whether Biernaux, C., Sels, A., Huez, G., and Stryckmans, P. (1996). Bone
Marrow Transplant. 17 Suppl. 3, S45–S47.differentiated cells with limited replicative capacity can
be transformed by acquiring self-renewal properties. Bose, S., Deininger, M., Gora-Tybor, J., Goldman, J.M., and Melo,
J.V. (1998). Blood 92, 3362–3367.Again, the study of CML sheds light on the notion that
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